Last reviewed · How we verify
NCT06824636
Per Kilogram Versus Nitrogen Balance Methods for Daily Protein Requirement in Cancer Patients
NA trial testing a personalized diet plan was prepared according to the calculated requirements of each patient by two expert dietitians in Nitrogen Balance in 103 participants. Completed in 30 March 2020.
30 January 2020
Quick facts
| Lead sponsor | Istanbul University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 103 |
| Start date | 1 September 2019 |
| Primary completion | 30 January 2020 |
| Estimated completion | 30 March 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- a personalized diet plan was prepared according to the calculated requirements of each patient by two expert dietitians
Conditions studied
- Nitrogen Balance — all drugs for Nitrogen Balance →
- Cancer — all drugs for Cancer →
- Protein Requirement — all drugs for Protein Requirement →
Sponsor
Istanbul University
Who can join
18 and older, any sex, with Nitrogen Balance or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to compare the effects of two dietary protein supplementation methods (per kg \[PK\] vs nitrogen balance equation \[NBE\]) on nutritional status, muscle strength, lean body mass, physical performance, and dietary compliance in cancer patients. The main questions it aims to answer are: Does the PK method improve muscle strength and lean body mass more effectively than the NBE method? Which method better supports nutritional status and physical performance in cancer patients? Are there differences in dietary compliance between the two methods? Researchers will compare the PK method (1.2-1.5 g/kg/day protein) to the NBE method (protein requirements based on nitrogen balance) to evaluate their impact on these outcomes. Participants will: Follow a personalized diet plan based on either the PK or NBE method Attend follow-up visits at weeks 4 and 8 for assessments of BMI, muscle mass, muscle strength, gait speed, serum albumin, and CRP Engage in moderate aerobic exercise (brisk walking) for at least 30 minutes a day, 5 days a week
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06824636
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Istanbul University trials
Trials by the same sponsor.
- NCT07472946 — Whole-Body Vibration Exercise in Patients With Parkinson's Disease · NA · not yet recruiting
- NCT07433894 — Scoliosis and Functional Outcomes in Children With Juvenile Idiopathic Arthritis · not yet recruiting
- NCT07420049 — Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study · not yet recruiting
- NCT07415967 — The Effect of a Dual-Task Technique-Based Exercise Program on Clinical Outcomes in Rotator Cuff Related Shoulder Pain · NA · recruiting
- NCT07473024 — pEEG-Guided Anesthesia and Behavioral Outcomes in Children · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06824636 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul University
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06824636.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing